Stay updated with breaking news from David Lassen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Prime Therapeutics LLC/Magellan Rx Management, LLC (Prime/MRx) continues to publish award-winning and industry-leading research on a range of...
Drugmakers and many doctors have been pushing for better insurance coverage of anti-obesity medications.
Around 32% of patients prescribed Novo Nordisk A/S's (NYSE: NVO) weight-loss drug, Wegovy, were still using the medication a year after their initial prescription, indicating a significant drop in adherence compared to what was
(Reuters) -Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk’s Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply, according to an analysis of U.S. pharmacy claims shared with Reuters. The annual cost of overall care for patients prior to taking Wegovy or a similar drug was $12,371, on average, according to the analysis. Medicines such as Wegovy can cost more than $1,000 per month, and any improvement in health and subsequent reduction in medical costs is not likely to occur quickly.
Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk's Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply, according...